Form 4: ATYR Pharma Director Acquires Stock Options

Paul Schimmel, a Director at ATYR Pharma Inc., acquired 50,000 stock options with an exercise price of $0.95, vesting in full on May 11, 2027, or the 2027 Annual Meeting.

Summary

• Paul Schimmel, a Director at ATYR Pharma Inc., was granted 50,000 stock options on May 11, 2026.
• The stock options have an exercise price of $0.95 per share.
• These options are set to vest in full on May 11, 2027, or at the company's 2027 Annual Meeting of Stockholders, whichever comes first.
• Vesting is contingent upon Mr. Schimmel's continued service on the Board of Directors.
• The filing indicates that Mr. Schimmel is not subject to Section 16 reporting requirements beyond this transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director Paul Schimmel has been granted a significant number of stock options (50,000), indicating a commitment to the company's future performance and alignment of incentives.
• The exercise price of $0.95 suggests the options are granted at or near the current market price, providing potential upside for the director if the stock price increases.

Risks

• The value of the stock options is entirely dependent on the future performance of ATYR Pharma's stock price.
• Continued service on the Board of Directors is a condition for vesting, meaning any departure from the board before the vesting date would result in forfeiture of the options.

Future Outlook

The grant of stock options to a director suggests management's confidence in the company's future prospects, as the value of these options is tied to stock price appreciation.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to attract and retain talent and align executive interests with shareholder value. This is a standard compensation mechanism within the industry.

Related Party Transactions

• Grant of 50,000 stock options to Director Paul Schimmel under the Issuer's non-employee director compensation policy.

Stakeholder Impact

• Shareholders: The grant of options aligns director incentives with shareholder interests, potentially leading to decisions that aim to increase stock value. Dilution is a minor consideration given the typical size of such grants relative to total shares outstanding.
• Employees: Standard compensation practice for directors, indirectly reinforcing the company's approach to executive compensation.
• Management: Reinforces the existing compensation structure for non-employee directors.

Next Steps

• Paul Schimmel to continue service on the ATYR Pharma Board of Directors to ensure vesting of stock options.
• ATYR Pharma to potentially hold its 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

ATYR Pharma, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing, Paul Schimmel